Director — Ham Jung Kyu: The resignation of Ham Jung Kyu did not result from any disagreement with the company.

Chief Operating Officer — Young Seung Ko: The company appointed Young Seung Ko as the Chief Operating Officer.

Other Events. On March 19, 2026, the United States District Court for the Northern District of Illinois (the “Court”) preliminarily approved the settlement (“Settlement”) of stockholder derivative claims brought on behalf of Exicure, Inc. (the “Company” or “Exicure”), as well as potential claims asserted by certain Exicure stockholders, in accordance with that certain Stipulation and Agreement of Settlement dated March 18, 2026. The Settlement is intended to fully and finally resolve the foll…

Director — Sangjin Yeo: Resigned from the Board of Directors and Audit Committee.

in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set fo…

CEO and President — Andy Yoo: Andy Yoo resigned as CEO and President, replaced by Jung Soo Kim.

CEO and President (Andy Yoo), CFO and Secretary (Seung Ik Baik) — Andy Yoo, Seung Ik Baik: The resignations of the CEO and CFO without named successors are significant departures.

Other Events Completion of Milestone 1 On January 16, 2026, Exicure, Inc. (the “Company”) achieved the first contractual milestone under its License and Collaboration Agreement (the “Agreement”) with GPCR Therapeutics Inc. The milestone relates to the completion of the Company’s Phase 2 clinical trial of its novel stem cell mobilizer (NCT05561751), which was achieved through the formal submission of the Clinical Study Report to the U.S. Food and Drug Administration on January 16, 2026. Under…

in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set fo…

Director: Four directors resigned and two new directors were appointed to the Board of Directors.

in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set fo…

in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set fo…

The company updated severance packages and adjusted the annual base salaries of its CEO and CFO.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 21, 2025, Exicure, Inc. (the “Company”) received a delinquency notification letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that due to the delay in filing the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (the “Form 10-Q”), the Company is not in compliance with Nasdaq Listing…

Entry into a Material Definitive Agreement On April 30, 2025, Exicure, Inc. (the “Company”) entered into a convertible bond agreement (the “Convertible Bond Agreement”) with KC Creation Co., Ltd. (“KC Creation”), the Company’s wholly owned South Korean subsidiary. Pursuant to the Convertible Bond Agreement, the Company purchased non-guaranteed private placement convertible bonds (the “Bonds”) of KC Creation for a subscription amount of 4.5 million KRW, or approximately $3.125 million USD. The…

Changes in Registrant's Certifying Accountant Based on information provided by Marcum LLP (“Marcum”), the independent registered public accounting firm of Exicure, Inc. (the “Company”), CBIZ CPAs P.C. (“CBIZ CPAs”) acquired the attest business of Marcum, effective November 1, 2024. Marcum continued to serve as the Company’s independent registered public accounting firm through April 10, 2025. On April 10, 2025, Marcum resigned as the Company’s independent registered public accounting firm, an…

in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set fo…

Director — Jiyoung Hwang, Paul Kang: Both Jiyoung Hwang and Paul Kang resigned from the Board of Directors for personal reasons.

Entry Into a Material Definitive Agreement Common Stock Purchase Agreement On February 14, 2024, Exicure, Inc. (the “Company”) entered into a Common Stock Purchase Agreement with Shin Chang Partners and RMS0718 Co., Ltd. (the “Purchasers”), pursuant to which the Company agreed to issue and sell to each of the Purchasers 145,454 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $5.50 per share. Other than in respect of the Common Sto…

Based in part upon the representations of the Purchasers in the Common Stock Purchase Agreement, the offering and sale of the securities will be made in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act. The sale of the securities will not involve a public offering and will be made without general solicitation or general advertising. The Purchasers represented that they are an accredited investor, as such term is defined in Rule 501(a) of Regulation D under the Secur…

Entry Into a Material Definitive Agreement On January 19, 2025, Exicure Inc. (“the Company”) entered into a Share Purchase Agreement with GPCR Therapeutics Inc, a Korean corporation, (“GPCR”) pursuant to which the Company acquired from GPCR all of the issued and outstanding equity securities of GPCR Therapeutics USA Inc., a California corporation (“GPCR USA”). The transactions contemplated under the Share Purchase Agreement closed concurrently with execution. GPCR USA was, until immediately p…

Director — Chang Keun Choi, Minwoo Kang: Appointment of new directors to the Board and their roles in the Audit Committee.

Other Events. As previously disclosed, on June 20, 2024, Exicure Inc. (the “Company”) was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Company no longer satisfied the minimum $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Equity Requirement”). The Company’s stockholders’ deficit as of March 31, 2024, was $2.2 million. The Company thereafter presented its plan to regain compliance with the Equity Requirement to a Nasdaq Hea…

Director: Multiple directors resigned and were replaced, leading to a significant change in the board composition.

Other Events. As previously disclosed, on June 20, 2024, Exicure Inc. (the “Company”) was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Company no longer satisfied the minimum $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market (the “Equity Requirement”). The Company’s stockholders’ deficit as of March 31, 2024, was $2.2 million. The Company thereafter presented its plan to regain compliance with the Equity Requirement to a Nasdaq Hea…